Exelixis' Strong Cabometyx Start Signals Changing Of Guard In Kidney Cancer Market

One of a trio of new drugs shaking up the kidney cancer market, Cabometyx (cabozantinib) does better than expected in its first nine weeks on the US market, and additional indications are on the near horizon.